Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SGN-15 (cBR96-doxorubicin immunoconjugate)
SGN-15 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| SGN-15, Docetaxel | DRUG | - |
| SGN-15 (cBR96-doxorubicin immunoconjugate) | DRUG | - |
| Taxotere (docetaxel) | DRUG | - |
| SGN-15 | DRUG | - |
| Docetaxel | DRUG | - |
Inclusion Criteria: * Patients with pathologically confirmed stage IIIB or IV NSCLC with a minimum of 1 measurable baseline target lesion who have received no prior chemotherapy for metastatic disease and are not eligible for combined modality therapy with curative intent * Patients must have an EC...
SGN-15 was studied in oncology for the treatment of non-small cell lung carcinoma and prostatic neoplasms, specifically hormone refractory prostate cancer. It was evaluated in Phase 2 clinical trials in combination with docetaxel. Both indications were investigated in adult patient populations in the United States.
SGN-15 was developed by Pfizer, Inc., which trades under the ticker PFE. The company sponsored the Phase 2 clinical program evaluating the agent in non-small cell lung carcinoma and prostate cancer. All listed trials for SGN-15 are completed.
SGN-15 is in Phase 2 development. It is an investigational agent and is not approved. Three Phase 2 trials have been completed, and no trials are currently active. The studies enrolled a total of 160 patients across non-small cell lung carcinoma and prostatic neoplasms.
SGN-15 has been evaluated in three completed Phase 2 trials: NCT00086333, which used FDG-PET to investigate SGN-15 and docetaxel in advanced non-small cell lung carcinoma; NCT00051571, a safety and efficacy study of the immunoconjugate with docetaxel in non-small cell lung carcinoma; and NCT00031187, which studied SGN-15 in hormone refractory prostate cancer.
Yes, SGN-15 is also known as cBR96-doxorubicin immunoconjugate. It is an antibody-drug conjugate that combines the cBR96 antibody with the chemotherapy agent doxorubicin. The agent has also been studied in combination with docetaxel in clinical trials.
SGN-15 was studied in non-small cell lung carcinoma as a treatment combined with docetaxel. Two completed Phase 2 trials, NCT00086333 and NCT00051571, evaluated the immunoconjugate in patients with advanced non-small cell lung carcinoma. Both studies were conducted in the United States in adults aged 18 years and older.